Media

Beth Calitri

Corporate Communications, Media Relations

978.417.2031

[email protected]

Sort by Year

February 3, 2021

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Investor Update Call

January 5, 2021

Ironwood Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

December 3, 2020

Ironwood Pharmaceuticals Appoints Jay P. Shepard to Board of Directors

November 6, 2020

Ironwood Pharmaceuticals to Present at the 29th Annual Credit Suisse Healthcare Conference

November 5, 2020

Ironwood Pharmaceuticals Reports Strong Third Quarter 2020 Results and Increases Full Year 2020 Financial Guidance

November 5, 2020

Ironwood Pharmaceuticals Appoints Alexander Denner, Ph.D., to Board of Directors

October 22, 2020

Ironwood Pharmaceuticals to Host Third Quarter 2020 Investor Update Call

September 29, 2020

Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment

September 2, 2020

Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences

August 6, 2020

Ironwood Pharmaceuticals Reports Second Quarter 2020 Results; Delivered GAAP Net Income of $25 Million and Adjusted EBITDA of $33 Million

July 23, 2020

Ironwood Pharmaceuticals to Host Second Quarter 2020 Investor Update Call

July 21, 2020

Ironwood Announces Updates Designed to Strengthen IW-3718 Phase III Program for Refractory Gastroesophageal Reflux Disease (GERD)

May 27, 2020

Ironwood and AbbVie Report Top-line Phase II Data for MD-7246 in Patients with Abdominal Pain Associated with Irritable Bowel Syndrome with Diarrhea (IBS-D)

May 6, 2020

Ironwood Pharmaceuticals Reports First Quarter 2020 Results and Provides Update on Impact of COVID-19 Pandemic

April 28, 2020

Ironwood and Allergan Receive Notices of Allowance for Patent Applications Covering 72 mcg Dose of LINZESS® (linaclotide)